Clinical Trial: Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06857786) titled 'Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients' on Jan. 08.

Brief Summary: To evaluate the safety and tolerability of satri-cel as consolidation therapy after postoperative adjuvant therapy in patients with resected gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Study Start Date: March 10

Study Type: INTERVENTIONAL

Condition: Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma

Intervention: DRUG: Drug: CT041 autologous CAR T-cell injection

The planned dose of satri-cel in this trial was 2.5 x 108 cells, single infusion. The trial will star...